After 2 weeks of HER2-targeted treatment, tumours classified as HER2-enriched or Basal-like by PAM50 at baseline showed significantly higher density of all 4 immune subsets as compared to Luminal A and B tumours (Table 1, Fig. 3b, Supplementary Fig. 16b). Here, ERBB2 is linked to neoplasm.